Targeted treatments with anti-EGFR monoclonal antibodies (cetuximab and panitumumab) are recommended by the National Comprehensive Cancer Network (NCCN) for metastatic CRC patients whose tumors do not harbor KRAS mutations [3, 4]. The gene discussed is EGFR; the disease is colorectal carcinoma.